Aardvark Appoints Clinical Leader to Board
Aardvark appointed biotech executive David Zhang to its board to aid development of ARD-101 for Prader-Willi Syndrome. Leadership appointments positively impact biopharma company strategy.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed